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TObjective: The left atrial appendage is a frequent source of thromboemboli in patients
with atrial fibrillation. Exclusion or excision of the left atrial appendage may reduce the
risk of stroke in patients with atrial fibrillation. We evaluated the ability of a novel
device to exclude the left atrial appendage during early and intermediate follow-up
periods in a canine model.
Methods: Eight mongrel dogs (mean weight 29.1  4.0 kg) were used in this study.
The occlusion device, constructed from 2 stainless steel strips covered with a knit
braided polyester fabric, was implanted at the base of the left atrial appendage
through a left thoracotomy on a beating heart. Dogs were evaluated at 7 days (n  2),
30 days (n  2), and 90 days (n  4) by epicardial echocardiography, left atrial
angiography, histologic inspection, and gross pathology.
Results: Device implantation was performed without complications in all animals.
Complete exclusion of the left atrial appendage from the circulation was confirmed
acutely and chronically by echocardiographic and angiographic evaluations. There
was no device migration or damage to adjacent structures.
Conclusion: This novel device enables rapid, reliable, and safe exclusion of the left
atrial appendage. The device provides a new therapeutic option for reducing the risk
of stroke in patients with atrial fibrillation.
Atrial fibrillation (AF) is associated with a 5-fold increase in the risk of stroke.1The majority of thrombi responsible for strokes in patients with AF arise fromthe left atrial appendage (LAA). In nonvalvular AF, 91% of atrial thrombi are
located in the LAA, almost always in the distal, trabeculated portion.2,3 Exclusion of the
LAA is a potential therapeutic option to reduce the risk of stroke in patients with AF,
particularly in patients who cannot be anticoagulated with warfarin sodium.4,5
Accordingly, there is a need for a simple, minimally invasive technique that
provides complete exclusion of the LAA. Recently, several novel techniques for LAA
exclusion using thoracoscopic or percutaneous approaches have been reported.6-10
Although an epicardial approach to LAA exclusion has the potential advantages of
simplicity (no transseptal puncture) and low procedural risk of embolism (no left
heart endocardial catheters), there is currently no instrumentation available to
facilitate rapid, reliable, and safe epicardial exclusion of the LAA.
A novel device, the atrial exclusion device (AED) (AtriCure, Inc, Cincinnati, Ohio),
has been specifically designed for the exclusion of structures such as the LAA. This
study was conducted to evaluate the ability of the AED to exclude the LAA during short
and intermediate follow-up periods in a canine model.
Material and Methods
AED Design
The AED is composed of a rigid and a flexible member fabricated from 316L stainless steel.
The members are completely covered with braided polyester knit sheath to promote ingrowth.
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ETThe AED has an internal major diameter of 35 mm and a neutral
spacing of approximately 1 mm between the steel members in the
closed position (Figure 1). The AED has 2 configurations: open, in
which distance between the members is greatest, and closed, in
which the AED changes to a closed, flattened shape. In the open
position, the AED is placed over the LAA and positioned at its
base. The device is then closed, and the position is confirmed.
Once the AED is in the closed position, the AED can be reopened
and reapplied if necessary.
The polyester covering on the AED serves 2 functions. It promotes
tissue ingrowth to securely anchor the AED onto the LAA without
damage to left atrial (LA) tissue adjacent to the occlusion site, and
it provides a soft covering for the AED to prevent trauma or
erosion into surrounding anatomic structures such as the pulmo-
nary artery and left ventricle.
In Vivo Study
Eight mongrel dogs (mean weight 29.1 4.0 kg) were used in this
study. This study was approved by the Cleveland Clinic’s Institu-
tional Animal Care and Use Committee, and all animals received
humane care in compliance with the “Guide for the Care and Use
of Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources, National Research Council, and published by
the National Academy Press, revised 1996.
Implant Study
All surgical procedures were performed using sterile techniques. The
animals were anesthetized with intravenous thiopental (20 mg/kg).
Anesthesia was maintained with isoflurane (0.5%-2.5%). The an-
imals were placed in the right lateral position. Electrocardiogram
leads were attached to the extremities. The left carotid artery was
used for continuous monitoring of arterial pressure.
A left fourth intercostal thoracotomy was performed, and the
pericardium was opened to expose the LAA. A 14-gauge an-
giocatheter was inserted into the left upper pulmonary vein to
monitor LA pressure and to inject contrast material for LA angiog-
raphy in the 60-degree left anterior oblique and 30-degree right
anterior oblique planes. Two-dimensional epicardial echocardiogra-
phy (2D EE) was performed to confirm blood flow into the LAA
before AED application. Hemodynamic data, including systemic ar-
terial and LA pressures and heart rate, were also collected at baseline.
Ventilatory support was transiently stopped during data-acquisition
periods. Hemodynamic parameters were digitized in real time at a
sampling rate of 200 Hz with a data-acquisition system (PowerLab,
AD Instruments, Inc, Mountain View, Calif) and stored on a hard disk
for subsequent analyses by a custom-made visual basic program on
Excel software (Excel 2000, Microsoft Corporation, Redmond,
Abbreviations and Acronyms
AED  atrial exclusion device
AF  atrial fibrillation
LA  left atrial
LAA  left atrial appendage
2D EE  two-dimensional epicardial echocardiographyWash).
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position was placed over the end of the LAA and aligned with the
base of the LAA. Once in the desired position, the AED was closed
by gently squeezing the flexible and rigid members together. If
AED deployment and position were not satisfactory, the AED was
simply repositioned and reapplied in the proper location. After
implantation, echocardiographic, angiographic, and hemodynamic
data were obtained as before.
The chest was closed with a chest drain tube in place. Animals
were followed for 7 days (2 dogs), 30 days (2 dogs), or 90 days
(4 dogs).
Explant Study
On the day of the explant study, animals were placed under general
anesthesia as for the implant study. The right femoral artery was
used for continuous monitoring of arterial pressure. The chest was
reentered through the original incision to expose the AED. Hemo-
dynamic assessment, LA angiography, and 2D EE were performed
in the same manner as during the implant study.
In one 7-day and two 90-day dogs, electrical stimulation was
applied to the LAA remnant. Standard epicardial pacing wires
were placed on the LA body and LAA remnant. LA pacing was
Figure 1. The atrial exclusion device (AED) consists of 2 stainless
steel, flexible and rigid members, each of which is bar-shaped.
Both members are covered with a braided polyester knit fabric. A,
AED without polyester fabric in the open position. B, AED without
polyester fabric in the closed position. C, AED with polyester
fabric in the open position.performed in asynchronous mode to confirm that the heart could be
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ETentrained. Then, stimulation (20 mA) was applied to 2 different
locations on the LAA to attempt to pace the heart at a rate greater
than the native sinus rate.
Before sacrifice, 500 U/kg of heparin was administered. Animals
were then put to death by rapid intravenous injection of sodium
pentobarbital (50 mg/kg) and potassium chloride (120 mEq). The
heart was excised with the AED in place, and the external and internal
surfaces of the LA were photographed and examined. The heart was
thoroughly investigated to evaluate the completeness of the LAA
Figure 2. AED implanted at the base of the LAA (A, B).
circumflex artery (small arrows), and great cardiac vei
atrial appendage; RVOT, right ventricular outflow trac
Figure 3. Gross anatomic views of the external LAA a
entire AED was covered with clear pink tissue with n
(B). LAA, Left atrial appendage; AED, atrial exclusion devic
The Journal of Thoracicexclusion, and surrounding tissue and structures were examined for
signs of damage and to evaluate tissue response.
Histologic Evaluation
Cardiac tissue specimens were excised from both sides of the AED
for evaluation of tissue ingrowth into the polyester fabric coating.
Tissue from the LAA distal to the implanted AED was also
evaluated. The tissues were fixed in formalin for 48 hours and
unding structures such as main pulmonary artery, left
rge arrow) were not affected by the AED (A). LAA, Left
he internal surface of the LAA orifice at 90 days. The
gration (A). Linear occlusion site (arrows) by the AEDSurro
n (la
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with hematoxylin-eosin.
Data Analysis
All values were expressed as mean  standard deviation. Repeated-
measures analysis of variance was used to assess differences be-
tween data at preimplantation, postimplantation, and follow-up.
Results
AED Implantation
The AED was implanted on a beating heart in all animals
without difficulty or hemodynamic change. AED applica-
tion required approximately 15 seconds once the LAA was
exposed. In 1 animal, initial AED position was unsatisfac-
tory because the device was not at the base of the LAA; the
AED was easily repositioned to ensure complete exclusion
of the LAA (Figure 2). Postimplant 2D EE and LA angio-
graphy revealed no communication between the LAA and LA
body in all animals. In addition, after implantation, Doppler
echocardiography confirmed absence of blood flow into the
LAA. All 8 dogs survived the procedure without device-
related complications. Postoperative recovery was unevent-
ful in all animals.
AED Explantation
At explantation, all AED clips remained positioned at the
base of the LAA with no evidence of migration. There was no
damage to adjacent cardiac structures; the LA body, circumflex
coronary artery, and pulmonary artery were intact without
erosion. In 7-day animals, there were mild adhesions be-
tween the AED and pericardium, and the LAA appeared
intact. In all but one 90-day dog there were dense adhesions
surrounding the AED, and the LAA had atrophied. In one
90-day animal, adhesions were only mild and the LAA was
flaccid but not atrophied. Before explantation, 2D EE and
LA angiography demonstrated no communication between
the LAA and LA in all animals. Doppler echocardiography
revealed no blood flow into the LAA in 7-day animals or in
the one 90-day animal without atrophy of the LAA. Hemo-
dynamic data revealed no significant changes among data at
preimplantation (heart rate: 123  14.3 beats/min, arterial
pressure: 102  20.5 mm Hg, and LA pressure: 10.6  1.7
mm Hg), postimplantation (heart rate: 124  16.4 beats/
min, arterial pressure: 101  19.2 mm Hg, and LA pressure:
10.9  2.0 mm Hg), and follow-up (heart rate: 122  9.9
beats/min, arterial pressure: 105  9.4 mm Hg, and LA pres-
sure: 10.6  1.9 mm Hg). Pacing studies performed in one
7-day dog and two 90-day dogs confirmed electrical isolation
of the LAA or LAA remnant.
Gross and Histologic Examinations
The heart was excised with the AED in place in all
animals. Examination of the inside of the LA revealed a
smooth endocardial surface at the origin of the LAA;
1642 The Journal of Thoracic and Cardiovascular Surgery ● Decthere was no cul-de-sac, and there was no thrombus
associated with the AED. In one 7-day animal, a 1-cm,
firmly adherent LA thrombus was identified arising from
the body of the LA directly opposite to the LAA orifice;
this likely represented a site of endocardial damage
caused by the catheter tip. There was no communication
between the orifice of the LAA and the thrombus, indi-
cating that there was no relationship between the throm-
bus formation and the AED application.
At 7 days, the distal LAA was intact. The polyester
fabric was covered with a thin, pink tissue. Figure 3
shows a representative gross anatomic view of the exter-
nal LAA and the internal surface of the LAA orifice at 90
days. Tissue ingrowth completely covered the AED and
the LAA was atrophied in 3 of 4 dogs (Figure 3, A). In
addition, the occlusion line was smooth and linear with-
out any trabeculated portions (Figure 3, B). Hematoxylin-
eosin–stained sections of the distal LAA tissue from
non-atrophied LAAs showed myocardium with fibrotic
remodeling and fatty infiltration, whereas the tissue from
atrophied LAAs was completely replaced by fibrous tis-
sue. In all cases, the polyester fabric was covered by
fibrous connective tissue.
Discussion
Key Findings
A novel device applied to the epicardial surface com-
pletely excluded the LAA from the systemic circulation
and did not migrate or cause damage to adjacent cardiac
structures in the first 90 days after implantation. In ad-
dition, the AED provided electrical isolation of the LAA
in 3 of 3 cases.
AF, Stroke, and the LAA
AF is responsible for 10% to 20% of strokes. Recent ran-
domized trials have demonstrated that anticoagulation sub-
stantially reduces, but does not eliminate, the risk of stroke
in patients with AF.1,11,12 However, anticoagulant therapy
with warfarin is associated with both major (1%-2%/year)
and minor (5%-10%/year) hemorrhagic complications.13,14
Because of the increased risk of anticoagulant-related com-
plications with advancing age, many physicians are reluc-
tant to prescribe anticoagulant therapy for elderly patients
with AF.13,14 In addition, many patients are not compliant
with anticoagulation. Because of these issues, recommended
guidelines for anticoagulation are followed in less than half
of outpatients with AF.4,5
A potential alternative or adjunctive approach to stroke
prevention in patients with AF is surgical management of
the LAA. The LAA is the primary site of thrombus forma-
tion in patients with AF. Approximately 60% of LA thrombi
in rheumatic AF form in the LAA, but this figure is 91% in
patients with nonrheumatic AF.2 These reports led to the
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ETrecommendation that the LAA be excised or excluded at the
time of mitral valve surgery.15 This strategy has been associ-
ated with a reduction in the risk of late stroke in patients
undergoing mitral valve surgery.16 In addition, early data sug-
gest that LAA excision or exclusion reduces the risk of stroke
in selected patients with nonvalvular AF.2,17
Techniques for LAA Management
Cardiac surgeons have used a variety of techniques to manage
the LAA. Suture ligation from the endocardial surface of the
LA requires the use of cardiopulmonary bypass and may be
associated with bleeding or injury to the circumflex coro-
nary artery. In addition, endocardial suture ligation is incom-
plete in 10% to 30% of patients, and incomplete exclusion may
predispose the patient to thromboembolic events.18-20 In con-
trast, external ligation or excision can be performed without
opening the LA and without cardiopulmonary bypass. Such
approaches may include suture ligation or use of cutting or
noncutting surgical staplers.10,21 These techniques can cause
troublesome bleeding if friable LA tissue tears.22 Epicardial
application of a purse-string suture or loop may fail to
occlude the LAA or may cause bunching of LA tissue; these
might predispose to thrombus formation on the endocardial
surface. In addition, these epicardial approaches, including
this AED application, incur the potential risk of periopera-
tive thromboembolism in patients with LAA thrombi that
extend to the orifice of the LAA, because of the required
manipulation of the LAA. Therefore, these approaches
should be avoided in this patient population.
More recently, percutaneous approaches to LAA exclu-
sion have been introduced. Several reports of preclinical
data and human feasibility trials document successful endo-
cardial application and the possibility of stroke prevention.6-9
However, residual flow around the occlusion device immedi-
ately after implant and at follow-up was observed in every
patient, and the importance of this finding is uncertain.8
The AED
Unlike most surgical staplers, the AED has been developed
specifically for exclusion of structures such as the LAA. It
is configured for open surgical or thoracoscopic placement.
It is easily placed on the beating heart and may be atrau-
matically repositioned if initial placement is unsatisfactory.
When compared with epicardial stapling devices, the AED
offers 2 advantages: (1) easy reapplication that ensures proper
placement onto the base of the LAA and (2) elimination of the
risk of bleeding that may originate along the occlusion (staple)
line. The promotion of distal LAA atrophy by the AED, as
indicated in our 30- and 90-day experiments, may eliminate
the possibility of late recanalization of the LAA lumen,
which is one of the potential problems of noncutting sta-
pling devices. Angiography and echocardiography con-
The Journal of Thoracicfirmed complete exclusion of the LAA at 7, 30, and 90 days
without damage to adjacent cardiac structures. The physical
characteristics of the device and tissue ingrowth around the
polyester covering prevented device migration. By 90 days,
the LAA generally atrophied, leaving a smooth endocardial
surface where its origin had been. Although there was no
thrombus in the vicinity of the LAA, 1 animal did have a LA
thrombus that was likely attributable to catheter-induced
trauma at angiography. At present, the AED is further
evolving to obtain confidence for clinical trial.
Limitations
These data include early follow-up in a relatively small
number of healthy animals. None of the animals had AF, so
the possibility of LA thrombus formation after AED appli-
cation in the setting of AF cannot be excluded. However,
the smooth endocardial surface at the origin of the LAA and
the absence of a cul-de-sac in this region are very encour-
aging. This study does not test the hypothesis that exclusion
of the LAA reduces the risk of stroke or other thromboem-
bolism in patients or animals with AF.
Further Clinical Implications
This study suggested that the AED can occlude and isolate
the LAA completely, safely, and rapidly without cardiopul-
monary bypass and provide favorable biocompatibility over
a mid-term period (90 days). The results may stimulate the
development of novel device that allows for the AED de-
ployment under a thoracoscopic approach.
To date, no report shows clear evidence of the role of
LAA exclusion in the prevention of strokes for patients with
nonvalvular AF. A randomized trial of LAA occlusion during
routine coronary artery bypass surgery (Left Atrial Appendage
Occlusion Study) is ongoing and will provide definitive evi-
dence about the LAA exclusion in patients without mitral
valve disease.23 Meanwhile, several reports have suggested
that the LAA may be one of the sources of thrombus in
patients with significant left ventricular dysfunction (eg,
dilated cardiomyopathy), even in those who maintain
sinus rhythm.24,25 If LAA exclusion is proven to reduce
stroke risk in patients with nonvalvular AF and to be free
from other complications, this novel device, the AED,
may be suitable not only for patients with nonvalvular AF
but also for the aforementioned high-risk patients in sinus
rhythm for prevention of embolic events resulting from
LAA thrombi.
Conclusion
The AED may provide an alternative or adjunctive thera-
peutic option for reducing the risk of stroke in patients
with AF.
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